MBX Biosciences, Inc. (MBX) fair value analysis
Nasdaq · Updated 2026-10-19
MBX price how computed
Valuation status
No fair-value estimate yetMBX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MBX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $49.61
- Sector
- Healthcare
- 12-month range
- $16.13–$70.70
- Market cap
- $2.39B
- From 52-week high
- -29.8%
- Shares outstanding
- 48.2M
- Rank in Healthcare by quality score
- #250 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
MBX Biosciences, Inc. is a biopharmaceutical company that develops therapeutic programs targeting obesity, metabolic disease, and other conditions. The company is headquartered in the United States and operates as a publicly traded entity on the Nasdaq exchange.
MBX currently ranks #250 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.39B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-2.41
- Debt / equity
- 0.01
- Shares outstanding
- 48.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 29 · oversold
- 50-day average
- $60.73
- 200-day average
- $44.60
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-14.7%)
2026-03 ▲ beat (+12.1%)
2025-12 ▲ beat (+17.9%)
2025-09 ▲ beat (+7.4%)
2025-06 ▲ beat (+24.7%)
2025-03 ▲ beat (+7.8%)
2024-12 ▲ beat (+19.8%)
2024-09 ▼ miss (-2.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 0 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $95.7
- Target vs last price
- +92.9%
What our data shows for MBX
- Shares are trading in the middle of their 12-month price range of $16.13–$70.70.
- The 14-day relative strength index sits at an oversold 29.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MBX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MBX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MBX's Relative Strength Index moved from neutral territory into oversold zone this week, according to TickrTrends' derived indicators. The healthcare sector stock's valuation verdict remains awaiting full valuation as of the current assessment period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MBX showed movement this week, with the RSI zone shifting from oversold to neutral territory. The Healthcare sector company maintains an awaiting full valuation verdict as of this report.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MBX stock undervalued?
TickrTrends has no fair-value estimate for MBX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MBX's TickrTrends verdict?
MBX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MBX compare to other Healthcare stocks?
MBX ranks #250 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MBX overbought or oversold?
MBX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does MBX report earnings next?
MBX's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does MBX usually beat earnings estimates?
Over its last 8 reported quarters MBX beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MBX?
Of 11 analysts covering MBX, 11 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $95.7 (+92.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.